Anagrelide (hydrochloride monohydrate)

Anagrelide hydrochloride monohydrate is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM) . Anagrelide hydrochloride monohydrate, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride monohydrate inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride monohydrate decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride monohydrate is a platelet-lowering agent and plays in the antithrombopoietic action[1][2][3].

Product Specifications

CAS Number

[823178-43-4]

UNSPSC

12352005

Hazard Statement

H302

Target

Apoptosis; Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/anagrelide-hydrochloride-monohydrate.html

Solubility

10 mM in DMSO

Smiles

ClC1=C(CN(C2)C3=NC2=O)C(N3)=CC=C1Cl.O.Cl

Molecular Formula

C10H10Cl3N3O2

Molecular Weight

310.56

Precautions

P264-P270-P330-P501

References & Citations

[1]Pescatore SL, et al. Anagrelide: a novel agent for the treatment of myeloproliferative disorders. Expert Opin Pharmacother. 2000 Mar;1 (3) :537-46. |[2]Mahajan R, et al. Phosphodiesterase inhibitors and their role in therapeutics[J]. Journal of Research in Medical Education & Ethics, 2013, 3 (2) : 115-123.